Impact of Sofosbuvir/Daclatasvir treatment on glycemic control and lipid profile in diabetic patients with chronic hepatitis C
Abstract Background and aim Limited data on the effects of direct-acting antiviral (DAA) drugs on glycemic control and lipid profiles in chronic hepatitis C (CHC) patients with type 2 diabetes mellitus (T2DM). Methods One hundred fifty-one treatment-naïve CHC patients with T2DM, not on insulin and w...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-07-01
|
| Series: | Egyptian Liver Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43066-025-00436-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Background and aim Limited data on the effects of direct-acting antiviral (DAA) drugs on glycemic control and lipid profiles in chronic hepatitis C (CHC) patients with type 2 diabetes mellitus (T2DM). Methods One hundred fifty-one treatment-naïve CHC patients with T2DM, not on insulin and with no prior diagnosis of hyperlipidemia, were treated with Sofosbuvir 400mg and Daclatasvir 60mg for 12 weeks. Laboratory tests included fasting blood sugar (FBG), hemoglobinA1c (HbA1c), fasting insulin, Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), low-density lipoprotein (LDL), total cholesterol, and triglycerides. Results Mean age 50.6 ± 5.6 years, 53% females. Significant baseline hyperlipidemia when compared to control group of 150 non diabetic CHC: total cholesterol (207.5 ± 31.6 vs 162 ± 24.1 mg/dL; p < 0.001), LDL (129.6 ± 18.2 vs 115.1 ± 9.2 mg/dL; p = 0.009) and triglycerides (177.6 ± 40.6 vs 151 ± 31.5 mg/dL; p = 0.02); with sustained virologic response (SVR) of 98.7 and 100%, respectively. Diabetic group patients who achieved SVR had significant improvements in labs after 12 weeks of treatment: FBG (137.9 ± 18.1 vs 113.3 ± 11.5 mg/dL; p < 0.001), HbA1C (8.3 ± 2.1 vs 6.5 ± 1.5; p < 0.001), fasting insulin (16.1 ± 2.1 vs 10.4 ± 2.3 µIU/mL; p < 0.001), HOMA-IR (5.4 ± 0.8 vs 2.8 ± 0.6; p < 0.001), total cholesterol (207.5 ± 31.6 vs 174.7 ± 28.2; p < 0.001), LDL (129.6 ± 18.2 vs 105.9 ± 16.2; p < 0.001) and triglycerides (177.6 ± 40.6 vs 142.9 ± 41.1; p = 0.004). Conclusion Diabetes negatively impacts lipid levels but does not reduce the high cure success rate of DAAs. Significant improvements in glycemic control, insulin resistance, and lipid profiles were observed in patients who achieved SVR, suggesting that HCV clearance in diabetic patients may enhance glucose and lipid homeostasis. |
|---|---|
| ISSN: | 2090-6226 |